Rheumatology 2000; 39: 1009-1013
© 2000 British Society for Rheumatology
Prediction of disease progression in early rheumatoid arthritis by ICTP, RF and CRP. A comparative 3-year follow-up study
Division of Rheumatology, Department of Internal Medicine, University of Oulu, Oulu,
1 Orton Rehabilitation Centre, Invalid Foundation, Helsinki,
2 Division of Rheumatology, Department of Medicine, Helsinki University Central Hospital, Helsinki,
3 Department of Clinical Chemistry, University of Oulu, Oulu,
4 Rheumatism Foundation Hospital, Heinola and
5 Helsinki City Hospital, Helsinki, Finland
Objective. To test the predictive value of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP; a marker of type I collagen degradation), rheumatoid factor (RF) and C-reactive protein (CRP) for disease progression in patients with early rheumatoid arthritis (RA)
Method. We tested the value of baseline values of RF, CRP and ICTP for the prediction of radiological joint progression over 3 yr in 63 consecutive patients with early RA who were treated with the ‘saw-tooth strategy’.
Results. Age- and sex-adjusted risks as odds ratios (95% confidence intervals) of elevated serum ICTP, RF positivity and increased CRP for progressive joint disease (defined as an increase of >20 in Larsen's index on radiographs of the hands and feet) were 3.9 (1.3, 11.9), 3.9 (1.0, 15.5) and 2.6 (0.9, 7.5), respectively. Better prediction was achieved when the tests were used in combination, and where there was both elevated ICTP and positive RF the odds ratio was 9.1 (2.5, 32.9). This test combination showed good sensitivity and specificity (71 and 77%, respectively), with a positive predictive value of 65% and a likelihood ratio of 3.1.
Conclusion. This kind of risk profile, in which the tests used reflect different aspects of the disease process, may be useful in early disease assessment to find patients who will need the most active drug therapy.
KEY WORDS: Prognosis, Joint destruction, Collagen degradation, ICTP, C-reactive protein, Rheumatoid factor, Rheumatoid arthritis.
Correspondence to: M. Hakala, Department of Internal Medicine, University of Oulu, FIN-90220 Oulu, Finland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. Emery, I. B. McInnes, R. van Vollenhoven, and M. C. Kraan Clinical identification and treatment of a rapidly progressing disease state in patients with rheumatoid arthritis Rheumatology, April 1, 2008; 47(4): 392 - 398. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Nishimura, D. Sugiyama, Y. Kogata, G. Tsuji, T. Nakazawa, S. Kawano, K. Saigo, A. Morinobu, M. Koshiba, K. M. Kuntz, et al. Meta-analysis: Diagnostic Accuracy of Anti-Cyclic Citrullinated Peptide Antibody and Rheumatoid Factor for Rheumatoid Arthritis Ann Intern Med, June 5, 2007; 146(11): 797 - 808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. S. Smolen, F. C. Breedveld, M. H. Schiff, J. R. Kalden, P. Emery, G. Eberl, P. L. van Riel, and P. Tugwell A simplified disease activity index for rheumatoid arthritis for use in clinical practice Rheumatology, February 1, 2003; 42(2): 244 - 257. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Berglin, R. Lorentzon, L. Nordmark, B. Nilsson-Sojka, and S. Rantapaa Dahlqvist Predictors of radiological progression and changes in hand bone density in early rheumatoid arthritis Rheumatology, February 1, 2003; 42(2): 268 - 275. [Abstract] [Full Text] [PDF]
|
|